Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation for Chronic Back and Leg Pain

2022 ◽  
Author(s):  
Nagy Mekhail ◽  
Robert M. Levy ◽  
Timothy R. Deer ◽  
Leonardo Kapural ◽  
Sean Li ◽  
...  
2018 ◽  
Vol 27 (8) ◽  
pp. 2035-2044 ◽  
Author(s):  
Kasra Amirdelfan ◽  
Cong Yu ◽  
Matthew W. Doust ◽  
Bradford E. Gliner ◽  
Donna M. Morgan ◽  
...  

2015 ◽  
Vol 96 (2) ◽  
pp. 340-348 ◽  
Author(s):  
Denise G. Tate ◽  
Martin Forchheimer ◽  
Charles H. Bombardier ◽  
Allen W. Heinemann ◽  
Holly D. Neumann ◽  
...  

2018 ◽  
Vol 24 (4) ◽  
pp. 325-335 ◽  
Author(s):  
Bridget A. Cotner ◽  
Lisa Ottomanelli ◽  
Danielle R. O'Connor ◽  
Eni N. Njoh ◽  
Scott D. Barnett ◽  
...  

2017 ◽  
Vol 34 (20) ◽  
pp. 2877-2882 ◽  
Author(s):  
R. Andrew Glennie ◽  
Juliet Batke ◽  
Nader Fallah ◽  
Christiana L. Cheng ◽  
Carly S. Rivers ◽  
...  

2021 ◽  
Vol 10 (18) ◽  
pp. 4085
Author(s):  
Jan Kallewaard ◽  
Jose Paz-Solis ◽  
Pasquale De Negri ◽  
Maria Canós-Verdecho ◽  
Hayat Belaid ◽  
...  

Given the differing mechanisms thought to underlie therapeutic sub- and supra-perception-based neurostimulative modalities, Spinal Cord Stimulation (SCS) systems designed for combined delivery of these approaches may help improve analgesic outcomes and quality of life, and reduce treatment failures. This multicenter, observational case-series evaluated 188 patients with chronic back and/or leg pain implanted with an SCS device capable of sequential or simultaneous delivery of sub-perception and supra-perception stimulation programming (i.e., combination therapy) at 16 sites in Europe. Following implantation, patients were provided with an array of advanced supra-perception programs (e.g., paresthesia-based SCS using multiple independent current sources), and a custom set of sub-perception programs optimized with specific waveforms and/or field shapes. A mean overall pain score of 7.9 ± 1.7 (Standard Deviation (SD)) was reported pre-trial (Baseline). Overall pain was reduced by 4.4 ± 2.8 points (NRS) at 3-months (n = 117) and at 12 months post-implant (n = 90), respectively (p < 0.0001). Substantial quality-of-life (EQ-5D-5L) improvement as assessed at last follow-up was also observed (n = 60). These results suggest that an implanted SCS device capable of combination therapy, while also enabled with patient-specific waveform optimization and stimulation field targeting capabilities, can enable highly effective pain relief and improve quality of life in patients suffering with chronic pain.


2020 ◽  
Vol 8 ◽  
pp. 205031212095136
Author(s):  
Thorsten Luecke ◽  
Deborah Edgar ◽  
Daniel Huse

Chronic pain has a major impact on sufferers and their families. The associated health care costs are substantial. In the context of increasing prevalence, effective treatment options are ever more important. 10 kHz spinal cord stimulation has been shown to effectively provide pain relief, aid in opioid reduction, and improve quality of life in patients with chronic intractable pain. The present review aims to summarize the clinical evidence related to the use of 10 kHz SCS in chronic back and/or leg pain. We searched the PubMed database between 2009 and 2 June 2020 for articles reporting clinical studies that included at least 10 human subjects permanently treated with a 10 kHz SCS system (Senza® system) for chronic back and/or leg pain for a minimum of 3 months. A randomized controlled trial (SENZA-RCT), as well as several prospective and retrospective studies, reported clinical outcomes in subjects with chronic back and leg pain treated with 10 kHz SCS. A high proportion of subjects (60%–80%) reported long-term response to therapy. Pain relief was provided without paresthesia. Other studies showed promising pain relief outcomes in subjects with back pain ineligible for spinal surgery, neuropathic limb pain, and in those with previously failed traditional low-frequency SCS. Most studies reported improved quality of life metrics and/or reduced opioid intake. Level 1 evidence has already been established for the use of 10 kHz SCS in treating chronic back and leg pain, corroborated by real-world, clinical experience. Exploratory studies also show the potential of the therapy in other refractory pain syndromes, although larger studies are desired to validate their findings. Overall, the literature suggests that 10 kHz SCS provides long-term pain relief in a high proportion of patients, along with improved quality of life and reduced opioid consumption.


2005 ◽  
Vol 61 (5) ◽  
pp. AB148
Author(s):  
Kevin T. White ◽  
Michelle M. Pepper ◽  
Barbara Walsh ◽  
James Hastinggs ◽  
Haiyan Miao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document